BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26521298)

  • 1. Comment on "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial".
    Vassilakopoulos TP; Apostolidis J; Angelopoulou MK
    Haematologica; 2015 Nov; 100(11):e480-1. PubMed ID: 26521298
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to comment by P. Vassilakopoulos and colleagues.
    Jaeger U; Praxmarer M; Greil R;
    Haematologica; 2015 Nov; 100(11):e482. PubMed ID: 26521299
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.
    Jaeger U; Trneny M; Melzer H; Praxmarer M; Nawarawong W; Ben Yehuda D; Goldstein D; Mihaljevic B; Ilhan O; Ballova V; Hedenus M; Hsiao LT; Au WY; Burgstaller S; Weidinger G; Keil F; Dittrich C; Skrabs C; Klingler A; Chott A; Fridrik MA; Greil R;
    Haematologica; 2015 Jul; 100(7):955-63. PubMed ID: 25911553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma.
    Tilly H; Morschhauser F; Salles G; Casasnovas RO; Feugier P; Molina TJ; Jardin F; Terriou L; Haioun C; Coiffier B
    Leukemia; 2013 Jan; 27(1):252-5. PubMed ID: 22733106
    [No Abstract]   [Full Text] [Related]  

  • 7. [Risk of reactivation of hepatitis B in patients with the lymphoma HBsAg negative , anti-HBc positive treated with rituximab-CHOP].
    Pariente A
    Rev Prat; 2014 Mar; 64(3):324. PubMed ID: 24851363
    [No Abstract]   [Full Text] [Related]  

  • 8. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
    Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
    Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis.
    Ochi Y; Hiramoto N; Ono Y; Yoshioka S; Tabata S; Yonetani N; Matsushita A; Imai Y; Ishikawa T
    Leuk Lymphoma; 2016 Aug; 57(8):1945-8. PubMed ID: 26689650
    [No Abstract]   [Full Text] [Related]  

  • 10. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
    Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
    Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian Follicular Lymphoma Diagnosed Due to Hydronephrosis.
    Noguchi S; Kimura Y; Shibano S; Ariake C; Iwasawa T; Oyama N; Sato H; Enomoto K; Takahashi N
    Intern Med; 2023 Jan; 62(2):293-298. PubMed ID: 35732447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategy for preventing hepatitis B reactivation in patients with resolved hepatitis B virus infection after rituximab-containing chemotherapy.
    Kusumoto S; Tanaka Y; Mizokami M; Ueda R
    Hepatology; 2014 Aug; 60(2):765-6. PubMed ID: 24347499
    [No Abstract]   [Full Text] [Related]  

  • 13. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
    Chan TS; Khong PL; Kwong YL
    Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
    [No Abstract]   [Full Text] [Related]  

  • 15. HBV reactivation in immunosuppressed patients: prevention or containment?
    Ludwig E
    Hepatology; 2014 Jun; 59(6):2062-4. PubMed ID: 24753022
    [No Abstract]   [Full Text] [Related]  

  • 16. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
    Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.
    Lerch K; Meyer AH; Stroux A; Hirt C; Keller U; Viardot A; Marks R; Schreiber S; Pezzutto A; Scholz CW
    Ann Hematol; 2015 Jun; 94(6):981-8. PubMed ID: 25645656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
    Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
    J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?
    Lunning MA; Armitage JO
    Haematologica; 2015 Jul; 100(7):853-5. PubMed ID: 26130511
    [No Abstract]   [Full Text] [Related]  

  • 20. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.